With June being Acne Awareness Month, it’s important to point out that acne affects up to 50 million people in the U.S. each year. Raising awareness can help to reduce misinformation and enhance understanding of appropriate treatment methods in order to support patients and physicians in managing this distressing skin condition. LiVDerm’s upcoming South Beach Symposium (SBS) in August includes a number of acne-related sessions, including treatment and various complications and challenges. Attending SBS is the perfect opportunity to enhance your knowledge and gain valuable insight into acne and so much more. Until we see you in Miami Beach this August, you can peruse LiVDerm's Acne Digital Education Hub to stay on the cusp of best practices in the management of acne in every patient population.
News from the FDA
The U.S. Food and Drug Administration (FDA) has denied the approval of Verrica’s VP-102 treatment for molluscum contagiosum. According to Verrica's Press Release, the reason for denial was due to an official action indicated (OAI) classification given to Sterling Pharmaceuticals Services, the manufacturing organization they used to manufacture the product. Verrica remarks that the denial is not specific to the manufacturing of VP-102, and they are currently working with Sterling Pharmaceuticals Services to offer appropriate options to the FDA as it relates to their OIA status. “Based on the successful PAI of VP-102 at Sterling and our understanding that the Division was ready to communicate our label, we believe our NDA meets the statutory standards for approval and that any issues at Sterling do not impact the manufacturing, quality, efficacy, or safety of VP-102,” commented Ted White, Verrica’s President and Chief Executive Officer. “However, we recognize that the Dermatology Division’s hands may be tied due to the reinspection issues at Sterling and thank them for their efforts working with us to date.”
The FDA has, however, approved Dermavant’s Vtama (tapinerof) cream for the treatment of plaque psoriasis. This 1% aryl hydrocarbon receptor agonist is the first topical treatment drug of its kind to be approved in over 25 years. Director of clinical research at Henry Ford Health and LiVDerm Advisory Board Member, Linda F. Stein Gold, MD, believes the drug to be effective and well-tolerated, stating, “I see this as an important new tool to help our psoriasis patients achieve success.” Catch Dr. Stein Gold's presentation at the 20th annual SBS this August 11-14th, 2022!
In Case You Missed It
In May, we recognized Hemangioma and Vascular Birthmark Awareness Month. These conditions can affect as many as 1 in 10 children, and one of the most difficult challenges is proper diagnosis. Having the knowledge and expertise to be able to identify the differences between hemangiomas and other vascular malformations is vital in the effective treatment and management of these conditions. Expert pediatric dermatologists Elaine C. Siegfried, MD, and Mercedes E. Gonzales, MD, will be sharing their insights on this topic at the Masters of Pediatric Dermatology Symposium (MOPD) this August 11-12. Join them in Miami Beach to advance your knowledge of this important subject.
Complimentary CME Highlight
Gaining a comprehensive understanding of how the gut microbiome plays a role in certain skin conditions such as acne, atopic dermatitis, and psoriasis is an important step in exploring the intricacies of potential treatment options. Expand your knowledge of this complex topic with LiVDerm’s complimentary course, The Gut-Skin Connection: The Microbiome and its Effects on the Skin. This interactive course has been compiled by our expert faculty and participants can earn up to three CME credits upon completion - but hurry, this free course expires on 6/15/22!
Free Attendance to SBS And MOPD For Students
As a medical student or resident, LiVDerm recognizes that exposure to first-class training and education Is advantageous in getting ahead and building a successful career. It is for this reason that we are offering medical students the opportunity to attend the South Beach Symposium (SBS) and Masters of Pediatric Dermatology Symposium (MOPD) absolutely free. This is an incredible opportunity to acquire vital clinical pearls from some of the industry’s leading experts in medical, aesthetic, and pediatric dermatology. A valid student ID is required.
